Aspartic Acid Market to Reach USD 189.5 Million by 2035

According to analysts at Vantage Market Research, the Global Aspartic Acid Market size is worth USD 112.4 Million in 2024 and is projected to reach USD 189.5 Million by 2035, growing at a CAGR (Compound Annual Growth Rate) of 6.7% from 2024 to 2035. Key trends of market includeincreasing demand for bio-based production, growing applications in artificial sweeteners, rise in dietary supplements, advancements in sustainable manufacturing processes, and expanding use in biodegradable plastics.

Market Overview

The demand for dietary supplements is rising as consumers become more aware of and accepting towards aspartic acid products. Aspartic acid is available in various forms such as powders, meals, and capsules, dietary supplements are increasingly popular. Aspartic acid plays a key role in boosting testosterone levels, enhancing muscle mass, and improving strength in men. With the growing global population, the demand for food and dietary supplements is expected to increase, especially in the fitness sector. 

The bio-economy focuses on the sustainable use of biological resources for the production of food, energy, and industrial products, including biodegradable chemicals. Aspartic acid, derived from renewable resources through fermentation processes, aligns well with this shift toward sustainability. As governments and private companies invest in bio-based innovations and the development of eco-friendly alternatives, aspartic acid is gaining traction for its applications in industries like biodegradable plastics, food additives, and pharmaceuticals.

Evonik strengthens competitiveness of its Animal Nutrition business

• In April 2023, Evonik is transforming the operating model of its Animal Nutrition business to further increase its customer focus, ensure competitiveness and enable further profitable growth. Moving forward, the amino acids business and the specialty nutrition business will operate separately and according to different models - in line with their respective requirements and market conditions

Key Takeaways from the Report

• North America dominated the market with 42.60% of market share in 2024. The market is driven by strong inclination towards health-conscious consumerism has spurred the use of artificial sweeteners
• Based on the Product, the L-Aspartic Acid category accounted for significant market share for 63.70% in 2024. The segment is driven by its substantial use in industries across pharmaceuticals, food and beverages, nutritional supplements, and other industrial sectors
• In 2024, by Application, Polyaspartic acid dominated the market share of 31.30%. This segment is widely used as a water treatment agent, a scale inhibitor, and a dispersant in various industrial processes

Top Companies

• Evonik Industries AG
• Prinova Group LLC
• Iris Biotech GmbH
• ChemPep Inc
• Tocris Biosciences
• Flexible Solutions Inc
• AnaSpec Inc
• Kyowa Hakko Bio Co. Ltd

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

Evonik and Shandong Vland Biotech form JV in China with focus on gut health products for animals

• In October 2023, Evonik China Co., Ltd and Shandong Vland Biotech Co., Ltd agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally. Evonik will be the majority shareholder in this joint venture with 55 percent of the shares. The joint venture, called Evonik Vland Biotech (Shandong) Co., Ltd. will have its headquarters in Binzhou, China, and is planned to enter the market in Q1/2024